BJMS
www.batnajms.net

Batna Journal of Medical Sciences 2025;12(4):28
https://doi.org/10.48087/BJMSoa.2025.12428

REVIEW ARTICLE

Mechanisms, clinical implications, and treatment strategies for autonomic health dysfunction in anxiety and depression

Majedul HOQUE

ABSTRACT

Disturbances in emotion regulation and physiological homeostasis characterize anxiety and depression, two of the most common mental health disorders worldwide. Emerging research implicates autonomic nervous system (ANS) dysfunction—specifically an imbalance between sympathetic and parasympathetic activity—in their pathogenesis. Patients with anxiety and depression exhibit altered heart rate variability, impaired baroreflex sensitivity, and disrupted hypothalamic–pituitary–adrenal (HPA) axis interactions, indicative of compromised autonomic regulation. This review highlights diverse autonomic disorders and etiologies associated with these conditions, critically explores the neurobiological mechanisms linking the ANS to affective disorders, and discusses potential therapeutic approaches aimed at restoring autonomic balance.

Keywords: Autonomic nervous system, depression, autonomic disorder, HRV, MSA.

Department of Pharmacy, Jahangirnagar University, Dhaka-1342, Bangladesh.

Received: 02 Nov 2025
Accepted: 22 Nov 2025

Correspondance to: Majedul HOQUE
E-mail : majed.pharmju44@gmail.com

1. INTRODUCTION

The autonomic nervous system (ANS) controls involuntary physiological functions including digestion, blood pressure, heart rate, and sexual desire. It belongs to the peripheral nervous system as a subcomponent. The enteric, parasympathetic, and sympathetic nervous systems are all a part of the autonomic nervous system. Afferent and efferent fibers found in the sympathetic nervous system (SNS) and parasympathetic nervous system (PNS) supply the central nervous system (CNS) with motor output and sensory input [1]. The basic activity levels of the parasympathetic and sympathetic nervous systems are known as sympathetic and parasympathetic tonus, and they are both always active. The former is found in the systemic arterioles, and the latter is found in the intestines. The heart's sympathetic activity rises with effort, but parasympathetic activity (parasympathetic tone) prevails at rest [2].

Two of the most common mental illnesses in the world are anxiety and depression, which frequently coexist and significantly increase the burden of disease worldwide. In addition to their significant psychological effects, these diseases are becoming more widely acknowledged as systemic conditions involving dysregulation of the autonomic nerve system (ANS), a vital network that controls metabolic, respiratory, and cardiovascular processes to maintain homeostasis. People with anxiety and depression have been shown to have autonomic dysfunction, which is defined by an imbalance between sympathetic and parasympathetic activity. This suggests that their emotional and physical symptoms have a physiological basis [3, 4].

There has been increasing evidence that the relationship between mood disorders and autonomic instability is mediated by neuroinflammation, chronic stress, and changes in the hypothalamic–pituitary–adrenal (HPA) axis. Common results include muted parasympathetic activity, elevated sympathetic tone, and decreased heart rate variability (HRV), which indicate a decreased capacity to adjust to both internal and external stimuli. The clinical significance of comprehending ANS abnormalities in these situations is highlighted by the fact that these disruptions not only worsen psychological symptoms but also raise the risk of cardiovascular morbidity and mortality [5-7].

From a therapeutic perspective, autonomic regulation-focused interventions—like medication, biofeedback, mindfulness exercises, and neuromodulation—offer encouraging paths toward comprehensive care. More accurate, mechanistically based approaches to treating anxiety and depression may result from investigating the reciprocal link between emotional regulation and autonomic function [8, 9]. The purpose of this article is to investigate the mechanism behind autonomic dysfunction in depression and anxiety, talk about its clinical implications, and look at novel therapeutic approaches that attempt to restore autonomic balance and enhance general mental and physical health outcomes.

2. POSSIBLE MECHANISMS OF HOW THE ANS IS LINKED TO ANXIETY AND DEPRESSION

In healthy individuals, the parasympathetic nervous system (PNS), mostly controlled by the vagus nerve, helps with rest and recovery. In contrast, the sympathetic nervous system (SNS) drives arousal and stress responses. A hyperactive SNS and an underactive PNS are often found in cases of anxiety and depression. This imbalance, which shows a lack of autonomic flexibility, leads to increased physiological arousal, a higher heart rate, and lower heart rate variability (HRV). Reduced vagal activity makes it harder to regulate emotions and cope with stress. Meanwhile, ongoing sympathetic dominance increases the perception of stress and extends symptoms of anxiety [10-12].

The ANS and the hypothalamic pituitary adrenal (HPA) axis work together closely during stress responses. Long-term activation of the HPA axis, which raises cortisol levels and impairs negative feedback mechanisms, is caused by emotional dysregulation in anxiety and depression and chronic psychological stress. Structures of the limbic system, including the hippocampus, amygdala, and prefrontal cortex—areas crucial for mood regulation and autonomic control—are altered by elevated glucocorticoid release. The result of this dysregulation is a feedback loop that sustains physiological hyperarousal and emotional discomfort by reinforcing sympathetic overactivity and suppressing parasympathetic tone [13, 14].

There is increasing evidence that neuroinflammation plays a significant role in emotional and autonomic disorders. Patients with anxiety and depression have been shown to have higher levels of pro-inflammatory cytokines, including C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6). These cytokines change vagal transmission and disrupt the metabolism of neurotransmitters, particularly dopamine and serotonin. Normally, the vagus nerve helps reduce inflammation through the cholinergic anti-inflammatory pathway. However, when vagal activity decreases, unmanaged inflammation can worsen mood symptoms and further disrupt autonomic function [15, 16].

Stress sensitivity can be increased by reduced serotonin availability, which can also decrease parasympathetic tone and enhance sympathetic drive. Similarly, increased noradrenergic activity raises sympathetic arousal and is linked to signs of anxiety disorders, such as perspiration, tachycardia, and restlessness. The brainstem nuclei that coordinate central autonomic output, including the locus coeruleus and the dorsal motor nucleus of the vagus, are impacted when these neurotransmitters are dysregulated [17].

According to neuroimaging research, the brain areas in charge of autonomic regulation exhibit both structural and functional changes in response to anxiety and sadness. The central autonomic network (CAN), which integrates emotional and physiological responses, is made up of the prefrontal cortex, anterior cingulate cortex, amygdala, and insular cortex. The top-down regulation of the ANS is disrupted by amygdala hyperactivity and prefrontal cortex hypoactivity, which leads to sympathetic overdrive and decreased vagal control. Both physiological indicators of autonomic imbalance and emotional dysregulation are correlated with such patterns [18, 19].

Genetic predispositions that impact stress reactivity and ANS control may make people more susceptible to anxiety and depression. Differences in genes that encode glucocorticoid receptors, serotonin transporters (such as 5-HTTLPR), and catecholamine-metabolizing enzymes affect how people react emotionally and autonomically to stress. Furthermore, long-term stress can cause epigenetic changes like DNA methylation or histone acetylation that change the expression of genes linked to the HPA axis and autonomic regulation, hence keeping maladaptive stress reactions [20, 21].

The cardiovascular and metabolic systems are impacted by the autonomic imbalance that is present in anxiety and depression. Chronic sympathetic activation raises the risk of heart disease and hypertension by causing endothelial dysfunction, elevated blood pressure, and changed baroreflex sensitivity. The apparent comorbidity between mood disorders and metabolic syndrome is also influenced by autonomic dysfunction, which affects metabolic processes like insulin sensitivity and lipid control.

3. AUTONOMIC DISORDER

An essential part of the human nervous system, the autonomic nervous system regulates involuntary bodily processes like heart rate, blood pressure, digestion, temperature regulation, and respiration in addition to preserving internal physiological equilibrium [22]. It

maintains homeostasis and reacts appropriately to changes in the environment by working automatically and without conscious thought. Autonomic disorder is the term used to describe the ailment that results from the ANS's malfunction [23]. A wide range of clinical symptoms affecting many organ systems can result from these disorders (**Table 1**), which can occur as primary conditions or as sequel conditions to other diseases.

Table 1. Major diseases and disorders of the autonomic nervous system.

Disorder	Description	Primarily affected function	Common symptoms
Autonomic Neuropathy	Damage to autonomic nerves regulating internal organs	Sympathetic and parasympathetic	Dizziness, fainting, abnormal sweating, GI issues, urinary problems
Postural Orthostatic Tachycardia Syndrome (POTS)	Abnormal heart rate increase upon standing	Sympathetic	Rapid heartbeat, dizziness, fatigue
Multiple System Atrophy (MSA)	Neurodegenerative disorder affecting autonomic and motor systems	Sympathetic and parasympathetic	Orthostatic hypotension, bladder dysfunction, motor problems
Riley-Day Syndrome (Familial Dysautonomia)	Genetic disorder affecting sensory and autonomic neurons	Sympathetic and parasympathetic	Lack of tears, blood pressure instability, GI problems
Baroreflex Failure	Impaired blood pressure regulation due to baroreceptor damage	Sympathetic	Extreme blood pressure fluctuations, headaches
Guillain-Barré Syndrome (Autonomic Variant)	Immune-mediated nerve inflammation	Both sympathetic and parasympathetic	Fluctuating blood pressure, arrhythmias, sweating problems
Diabetic Autonomic Neuropathy	Nerve damage from chronic diabetes	Sympathetic and parasympathetic	Sexual dysfunction, orthostatic hypotension
Horner’s Syndrome	Damage to sympathetic pathway to the eye and face	Sympathetic	Ptosis, miosis, anhidrosis

4. REASONS FOR AUTONOMIC DYSFUNCTION

The peripheral autonomic nervous system is mediated by a number of commonly prescribed medications used to treat conditions that would otherwise appear to be unrelated, such as depression, hypertension, heart failure, asthma/airways disease, overactive bladder outlet obstruction, Alzheimer's-type dementia, and glaucoma. As a result, these medications may exacerbate or conceal autonomic dysfunction [24]. The progressive loss of autonomic neurons in pure autonomic failure (PAF), a degenerative disease, causes extensive autonomic failure, including severe orthostatic hypotension, urine incontinence, and decreased sweating. Alpha-synuclein buildup, a characteristic protein also shown in Parkinson's disease, is likely to be the cause, as it interferes with autonomic ganglia nerve signaling [25].

Multiple system atrophy is a neurological illness that causes extensive harm to the brainstem and basal ganglia, two areas that control movement and autonomic processes. Cerebellar ataxia, severe autonomic dysfunction, and parkinsonian symptoms are common presentations. Alpha-synuclein builds up abnormally in oligodendrocytes, which is the root reason and causes neuronal degeneration [26]. This condition, which is frequently brought on by mutations in the PHOX2B gene, impacts the brainstem regions that control respiration and autonomic reactions. During sleep, patients have poor breathing and reduced autonomic reactions to elevated carbon dioxide or low oxygen levels [27]. Autonomic dysreflexia is frequently linked to spinal cord injuries that occur above the T6 level. Unknown stimuli, such as a blocked urine catheter, fecal impaction, or pressure sores, can cause malignant hypertension to appear abruptly. The key to treating autonomic dysreflexia is identifying and controlling the triggering stimuli.

The most common cause of secondary autonomic dysfunction is diabetes. Diabetic autonomic neuropathy is caused by long-term hyperglycemia that affects peripheral nerves and tiny blood vessels. Orthostatic hypotension, resting tachycardia, decreased sweating, gastroparesis, and bladder dysfunction are typical symptoms. The length of the illness and inadequate glycemic management are major risk factors [28]. Some bacterial or viral infections can cause immune-mediated nerve damage or directly harm autonomic fibers. Notable instances include post-viral dysautonomia following infections with the Epstein-Barr virus, Lyme disease, or COVID-19, and

Guillain-Barré syndrome (GBS), particularly its subtype acute autonomic neuropathy. A growing number of post-COVID complications have been recorded, including postural orthostatic tachycardia syndrome (POTS) [29, 30].

Degeneration of the brain's autonomic centers and peripheral autonomic neurons is a common feature of conditions like Parkinson's disease, Alzheimer's disease, and Lewy body dementia. For example, autonomic symptoms including constipation, urine retention, and orthostatic hypotension may manifest before motor symptoms in Parkinson's disease [31, 32]. Peripheral and autonomic neuropathy can result from deficiencies in vitamins necessary for nerve function, including thiamine (B1), niacin (B3), and vitamin B12. Common underlying causes include malabsorption syndromes, prolonged alcoholism, and malnutrition [33]. Functional autonomic imbalance has a substantial correlation with depression, anxiety, and long-term stress. Prolonged sympathetic nervous system activation and parasympathetic activity suppression can cause hypertension, gastrointestinal disorders, and an accelerated heartbeat. These functional changes could eventually result in biochemical and structural modifications in autonomic circuits.

Autonomic nerves may be unintentionally harmed by some medical procedures. Radiation therapy, pelvic procedures, and neck or thoracic surgery, for instance, might cause sympathetic or parasympathetic fiber damage, which can result in regional autonomic dysfunction. Similar to this, nerve severing during organ transplant procedures can change autonomic reflexes.

5. AUTONOMIC DYSFUNCTION AND DEPRESSION

The sympathetic nervous system is more active when a person is under stress or is in a situation that is upsetting to them. In cases of mild depression, the sympathetic nervous system is engaged, whereas in cases of severe depression, the parasympathetic nervous system is active [34]. Changes in mood are frequently accompanied by autonomic changes. Decreases in heart rate variability (HRV) indices reflect changes in autonomic nervous system function that encourage vagal withdrawal. Decreased HRV is associated with prefrontal brain hypoactivity and is characterized by emotional dysregulation, diminished psychological flexibility, and impaired social interaction. The notion that HRV might serve as a helpful endophenotype for psychological and physical disorders is supported by this data [35].

A model of neurovisceral integration in relation to emotion regulation and dysregulation was presented by Thayer and Lane [36]. The authors assert that the ability to control one's emotions has significant health consequences. In circumstances where emotional control is necessary, HRV is a useful tool. According to the authors, people with greater baseline HRV levels exhibited context-appropriate emotional reactions; additionally, phasic activations in HRV in response to emotional change-requiring conditions have made successful emotional regulation easier [36].

Depression and autonomic dysfunction are related because they influence emotional and physiological reactions. The parasympathetic nervous system (PNS), which is mostly mediated by the vagus nerve, controls "rest and digest" processes, whereas the sympathetic nervous system (SNS) controls the body's "fight or flight" responses. Parasympathetic (vagal) tone falls and sympathetic activity becomes hyperactive in depression, which frequently upsets this equilibrium [35, 37]. Because of this imbalance, the body becomes autonomically stiff, making it less able to adjust to stress and environmental demands. Less HRV, which is a common indicator of reduced parasympathetic activity, is one of the most reliable biological indicators found in mania patients.

Serotonin, norepinephrine, and dopamine are monoamines that play a key role in mood control and autonomic functions. For example, lower vagal tone is connected to reduced serotonin levels. On the other hand, higher norepinephrine leads to tachycardia, anxiety, and restlessness, boosting sympathetic activity. The emotional and physical signs of depression arise from these neurotransmitter issues [38]. Neuroimaging studies show that the central autonomic network, which includes the prefrontal cortex, anterior cingulate cortex, amygdala, insula, and hypothalamus, is disrupted in depression. In depressed individuals, the autonomic nervous system is poorly regulated from the top down. This occurs because of hyperactivity in the amygdala and reduced activity in the prefrontal brain, which strengthens sympathetic dominance. Symptoms include increased heart rate, sleep disturbances, and impaired emotional regulation [39, 40].

6. AUTONOMIC FUNCTION IN EMOTION PROCESSING

The term "emotion regulation" describes how people alter, sustain, or manage their feelings, including how they manifest, experience, and react physiologically [41]. This involves a variety of techniques for controlling emotional experiences and their effects on behavior and thought processes, including expressive suppression, cognitive reappraisal, and attentional deployment. Emotional regulation can be maladaptive, which leads to interpersonal problems and psychopathology, or adaptive, which supports psychological welfare and social functioning. Emotional processing, on the other hand, describes the mental and emotional processes that go into evaluating, interpreting, and reacting to emotional inputs [42]. Perceptual, attentional, and memory functions are all included, along with higher-

order cognitive functions including problem-solving and cognitive reappraisal. Individual variations in emotion regulation and dysregulation, as well as social and cultural influences, can all have an impact on emotional processing.

Numerous physiological functions, such as emotion processing, communication, and regulation, are known to be influenced by the vagus nerve, a sophisticated network of nerve fibers that starts in the brainstem and runs throughout the body [43]. It appears that several vagal control systems are behaviorally related to social communication, mobilization, and immobilization and are phylogenetically ordered [43]. When emotional information is encoded or retrieved, the ANS may be activated, which could alter the neural mechanisms underlying mood-congruent memory [44]. At the nerve system level, the brain and ANS simultaneously regulate all peripheral systems, affect mood states, and regulate emotional processing and regulation [45, 46]. Emotions have been functionally associated with the brain's ability to predict bodily states. Ascending body or interoceptive signals, such as those sent by the vagus nerve, are continuously compared to the predictions [47].

7. CLINICAL IMPLICATIONS OF AUTONOMIC DYSFUNCTION

The effects of autonomic dysfunction on the cardiovascular system are among the most serious. By carefully balancing sympathetic and parasympathetic activity, the ANS typically keeps proper blood pressure and heart rate. This equilibrium is upset in autonomic dysfunction, resulting in orthostatic hypotension, a condition in which standing causes a large drop in blood pressure, which can cause fatigue, dizziness, and fainting. Postural orthostatic tachycardia syndrome (POTS), which causes palpitations and weakness when standing, is a condition that certain patients may have [48].

The central nervous system and autonomic dysfunction are closely related, and disruptions in the former frequently show up as neurological and psychiatric symptoms (Table 2). Autonomic dysfunction frequently precedes the onset of motor or sensory symptoms in illnesses including Parkinson's disease, multiple system atrophy (MSA), and diabetic neuropathy [49]. Implications for psychiatry are very important. Anxiety, sadness, and panic disorders are closely tied to disruptions in the autonomic nervous system, which regulates emotions and stress responses. Physiological arousal can increase when there is lower parasympathetic tone and higher sympathetic activity. This can result in emotional instability and chronic stress. Furthermore, problems with the autonomic system can affect attention, memory, and decision-making by reducing blood flow to the brain, which can lead to cognitive decline.

Table 2. Clinical implications of autonomic dysfunction in anxiety and depression.

System affected	Clinical manifestation	Underlying autonomic reason
Cardiovascular System	Elevated heart rate, increased blood pressure variability, palpitations	Sympathetic overactivityand reduced vagal tone
Respiratory System	Rapid or shallow breathing, dyspnea, hyperventilation	Autonomic imbalance affecting respiratory rhythm
Neuroendocrine/Metabolic	Increased cortisol, impaired glucose tolerance	Dysregulation of hypothalamic–pituitary–adrenal (HPA) axis and sympathetic drive
Sleep regulation	Insomnia, poor sleep quality, frequent awakenings	Reduced parasympathetic activity during sleep, elevated sympathetic tone
Cognitive/Emotional Regulation	Impaired concentration, emotional instability	Autonomic dysregulation impacting the limbic system
Gastrointestinal System	Nausea, abdominal discomfort, irritable bowel symptoms	Altered gut–brain axis and vagal dysfunction
Thermoregulatory System	Sweating, cold extremities, heat intolerance	Increased sympathetic activity

Autonomic regulation is important for the movement and secretion in the gastrointestinal tract. Gastroparesis is a condition characterized by slow stomach emptying. It can lead to bloating, nausea, and vomiting, and it can be triggered by autonomic dysfunction. Constipation, diarrhea, or changes in bowel habits are also common symptoms of Parkinson's disease and diabetic autonomic neuropathy [50, 51]. Autonomic regulation also affects the urogenital system. Significant discomfort and social misery can result from nocturia, incontinence, and urine retention caused by dysautonomia. Another big worry is sexual dysfunction; women may have trouble getting an orgasm or have decreased vaginal lubrication, while males may have erectile dysfunction [52]. Autonomic abnormalities are often associated with thermoregulation issues. Hyperhidrosis, or excessive perspiration, can cause discomfort and social embarrassment, whereas anhidrosis, or decreased perspiration, can lead to heat intolerance. These problems with temperature regulation demonstrate how much homeostasis can be upset by autonomic dysfunction [53].

The control of sleep-wake cycles is impacted by autonomic instability, which can lead to non-restorative sleep, excessive daytime drowsiness, and insomnia. People with autonomic dysfunction frequently experience chronic weariness and poor sleep, which exacerbates the consequences of other illnesses. Pain, psychological stress, and physical limitation all work together to drastically reduce everyday functioning and quality of life.

8. AUTONOMIC DYSFUNCTION TREATMENT

Autonomic dysfunction treatment requires a thorough, customized strategy that addresses the root cause as well as symptoms. While behavioral and lifestyle changes are essential for long-term maintenance, pharmaceutical treatments can normalize blood pressure, heart rate, and other autonomic processes [54, 55]. The goals of treating autonomic dysfunction include symptom management, underlying cause correction, and quality of life enhancement. It frequently calls for a multidisciplinary strategy that includes physical rehabilitation, lifestyle modifications, and medication. While metoclopramide or domperidone enhance gastrointestinal motility, medications like fludrocortisone, midodrine, and beta-blockers aid with blood pressure and heart rate regulation. Major treatment approaches for autonomic dysfunction are listed in Table 3) [54-59]. Pharmacological treatment modalities for autonomic dysfunction are shown in Table 4. For those with autonomic dysfunction, early identification and integrated care are crucial to avoiding problems, increasing functional ability, and improving overall quality of life.

Table 3. Key strategies for treating autonomic dysfunction.

Category	Treatment type	Clinical effect	Examples of therapy
Pharmacological	Beta-blocker	Lower heart rate, tremor, palpitations in anxiety	Propranolol, Atenolol
	Selective serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor.	Improve HRV, reduce sympathetic dominance in depression	Sertraline, Venlafaxine
	Tricyclic antidepressants (TCAs)	Effective in depression with autonomic symptoms	Amitriptyline, Nortriptyline
	Anxiolytics (benzodiazepines)	Decrease physiological arousal and anxiety	Alprazolam, Diazepam (short-term use)
	Alpha-2 agonists	Stabilize blood pressure and pacify mentality	Clonidine, Guanfacine
	Mineralocorticoids	Improve standing blood pressure, reduce dizziness	Fludrocortisone, Midodrine
Behavioral	Mindfulness & meditation	Lower cortisol, improve HRV, reduce anxiety	Mindfulness-Based Stress Reduction (MBSR) program
	Yoga & Tai-chi	Improve HRV, balance ANS, lower blood pressure	Regular practice 3–4×/week
	Aerobic exercise	Reduce resting heart rate, improve mood	Walking, cycling, swimming
	Sleep Hygiene & Stress Management	Improve mood, cognitive clarity	Consistent sleep and relaxation technique
Nutritional/Phytomedicine	Adaptogens	Enhance resilience, restore ANS balance	*Withania somnifera, Rhodiola rosea, Panax ginseng*
	Polyphenols	Support cardiovascular–autonomic health	Curcumin, Resveratrol, Green tea catechins
	Omega-3 Fatty Acids	Reduce depressive and autonomic symptoms	Fish oil, Flaxseed oil
	Group B vitamins and vitamin-D	Calm nervous system, lower stress reactivity	Food supplements and grains
Supportive	Cognitive-Behavioral Therapy (CBT)	Enhances physiological regulation and tolerance	Gold standard for anxiety and depression
	Hydration & Salt Intake	Prevents dizziness and fatigue	Useful in orthostatic condition
	Avoidance of stimulants	Reduces palpitations, hyperarousal	Limit caffeine, nicotine, alcohol
Neuromodulation Therapies	Transcranial Magnetic Stimulation (TMS)	Improves mood and HRV in depression	Repetitive TMS sessions
	Deep Breathing & Baroreflex Training	Lowers high blood pressure, enhances calmness	6 breaths/min, daily sessions

Table 4. Pharmacological treatment modalities for autonomic dysfunction with their dosage regimens (typical adult doses).

Medication type	Drug/therapy	Mechanism	Dosage ranges (Adults)
Sympathomimetic Agents	Midodrine	α1-adrenergic agonist → vasoconstriction	2.5–10 mg orally 3 times/day (avoid within 4 hours of bedtime)
	Droxidopa	Norepinephrine precursor → increases blood pressure	100–600 mg 3 times/day
Volume Expanders	Fludrocortisone	Mineralocorticoid → increases sodium & water retention	0.05–0.2 mg once daily
β-Blockers	Propranolol	β-adrenergic blockade → reduces tachycardia	10–20 mg 2–3 times/day
	Bisoprolol	β1-selective blocker	2.5–5 mg once daily
Cholinesterase Inhibitors	Pyridostigmine	Inhibits ACh breakdown → enhances parasympathetic tone	30–60 mg 2–3 times/day
Central agent	Clonidine	α2-agonist → reduces sympathetic outflow	0.1 mg 2–3 times/day
	Methyldopa	Central α2-agonist	125–250 mg 2–3 times/day
Serotonergic Agents	Fluoxetine	Enhances serotonin secretion → stabilizes blood pressure and heart rate	10–20 mg once daily
	Citalopram	Enhances serotonin availability → stabilizes blood pressure and heart rate	10-30 mg per day
Norepinephrine Reuptake Inhibitors	Atomoxetine	Increases Norepinephrine availability	10–40 mg once daily
Adjunctive Therapies	Erythropoietin	Increases red cell mass → raises blood pressure	25–50 IU/kg 2–3 times/week (subcutaneous)

9. FUTURE DIRECTIONS

Autonomic dysfunction often presents complex and overlapping symptoms, which makes diagnosis difficult. Future research should focus on creating precise, non-invasive diagnostic tools (Figure 1). AI-assisted tests for autonomic functions, heart rate variability analysis, and wearable biosensors are some methods that could aid in early detection and real-time monitoring. Using remote diagnostics and digital health platforms can also provide ongoing assessment of autonomic indicators in everyday life. This approach could enhance diagnostic accuracy and customize treatment according to individual needs [60]. Finding reliable biomarkers is crucial for understanding the causes and progression of autonomic diseases. Future studies are expected to focus on genetic, protein, and metabolic profiling to identify molecular markers associated with different types of autonomic dysfunction. If we gain a better understanding of neuroinflammation, oxidative stress, and mitochondrial dysfunction, new treatment options may arise. Additionally, exploring the gut-brain axis could shed light on how changes in the microbiome influence autonomic function [61, 62].



Figure 1. Future diagnostic tools for autonomic dysfunction.

Conventional drug treatments often cure symptoms but do not address the root causes. Future therapies might focus on neuromodulation techniques, stem cell therapy, and neuroprotective substances. For example, transcranial magnetic stimulation, vagal nerve stimulation, and bioelectronic medicine could help restore autonomic balance. New advancements in gene editing technologies, such as CRISPR, may enable us to fix genetic defects associated with certain autonomic dysfunction. The strong connection between mental health and the autonomic nervous system highlights the need for treatments that work together. Future care models should include behavioral interventions, mindfulness exercises, and psychological therapy along with medical treatments. Research into the links between stress, mood disorders, and autonomic dysfunction could lead to better management techniques.

10.CONCLUSION

Autonomic dysfunction is a major sign of anxiety and depression. It connects emotional struggles with physical health problems. The imbalance between too much sympathetic activity and not enough parasympathetic activity leads to emotional issues, higher cardiovascular risk, and difficulty coping with stress. Therefore, it is crucial to monitor autonomic functions, as this may reduce the symptoms of these conditions. Treating autonomic dysfunction can lower the related health risks and deaths. There is a chance for better treatment of these disorders with methods that restore balance in the autonomic system. These methods can include medication, therapy, and natural remedies. By adding autonomic assessment to psychiatric evaluations, we can detect issues early, provide personalized treatment, and achieve better long-term outcomes.

Competing interests: The authors declare that they have no competing interest.

Funding: This research received no external funding.

REFERENCES

1. Waxenbaum JA, Reddy V, Varacallo MA. Anatomy, Autonomic Nervous System. In: StatPearls. Treasure Island (FL): StatPearls Publishing; [updated 2023 Jul 24]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539845/
2. Guyton AC, Hall JE, Tuan DXA, Coquery S. Précis de Physiologie Médicale. Paris: Piccin; 2003.
3. Yang X, Fang Y, Chen H, Zhang T, Yin X, Man J, et al. Global, regional and national burden of anxiety disorders from 1990 to 2019: results from the Global Burden of Disease Study 2019. *Epidemiol Psychiatr Sci*. 2021 May 6;30:e36. doi:10.1017/S2045796021000275.
4. Niles AN, Dour HJ, Stanton AL, Roy-Byrne PP, Stein MB, Sullivan G, et al. Anxiety and depressive symptoms and medical illness among adults with anxiety disorders. *J Psychosom Res*. 2015 Feb;78(2):109–15. doi:10.1016/j.jpsychores.2014.11.018.
5. Bao AM, Swaab DF. The human hypothalamus in mood disorders: The HPA axis in the center. *IBRO Rep*. 2018 Dec 14;6:45–53. doi:10.1016/j.ibror.2018.11.008.
6. Smith JA, Pati D, Wang L, de Kloet AD, Frazier CJ, Krause EG. Hydration and beyond: neuropeptides as mediators of hydromineral balance, anxiety and stress-responsiveness. *Front Syst Neurosci*. 2015;9:46. doi:10.3389/fnsys.2015.00046.
7. Borkowski P, Borkowska N. Understanding Mental Health Challenges in Cardiovascular Care. *Cureus*. 2024 Feb 18;16(2):e54402. doi:10.7759/cureus.54402.
8. Hofmann SG, Gómez AF. Mindfulness-Based Interventions for Anxiety and Depression. *Psychiatr Clin North Am*. 2017 Dec;40(4):739–49. doi:10.1016/j.psc.2017.08.008.
9. Hofmann SG, Sawyer AT, Witt AA, Oh D. The effect of mindfulness-based therapy on anxiety and depression: A meta-analytic review. *J Consult Clin Psychol*. 2010 Apr;78(2):169–83. doi:10.1037/a0018555.
10. Tindle J, Tadi P. Neuroanatomy, Parasympathetic Nervous System. In: StatPearls. Treasure Island (FL): StatPearls Publishing; [updated 2022 Oct 31].
11. Siepmann M, Weidner K, Petrowski K, Siepmann T. Heart Rate Variability: A Measure of Cardiovascular Health and Possible Therapeutic Target in Dysautonomic Mental and Neurological Disorders. *Appl Psychophysiol Biofeedback*. 2022 Dec;47(4):273–87. doi:10.1007/s10484-022-09572-0.
12. Weissman DG, Mendes WB. Correlation of sympathetic and parasympathetic nervous system activity during rest and acute stress tasks. *Int J Psychophysiol*. 2021 Apr;162:60–8. doi:10.1016/j.ijpsycho.2021.01.015.
13. Herman JP, McKlveen JM, Ghosal S, Kopp B, Wulsin A, Makinson R, et al. Regulation of the Hypothalamic-Pituitary-Adrenocortical Stress Response. *Compr Physiol*. 2016 Mar 15;6(2):603–21. doi:10.1002/cphy.c150015.
14. Sic A, Bogicevic M, Brezic N, Nemr C, Knezevic NN. Chronic Stress and Headaches: The Role of the HPA Axis and Autonomic Nervous System. *Biomedicines*. 2025;13(2):463. doi:10.3390/biomedicines13020463.
15. Rengasamy M, Marsland A, Spada M, Hsiung K, Kovats T, Price RB. A chicken and egg scenario in psychoneuroimmunology: Bidirectional mechanisms linking cytokines and depression. *J Affect Disord Rep*. 2021 Dec;6:100177. doi:10.1016/j.jadr.2021.100177.
16. Cătălina GR, Gheorman V, Gheorman V, Forțofoiu M-C. The Role of Neuroinflammation in the Comorbidity of Psychiatric Disorders and Internal Diseases. *Healthcare (Basel)*. 2025;13(7):837. doi:10.3390/healthcare13070837.
17. Liu Y, Zhao J, Fan X, Guo W. Dysfunction in Serotonergic and Noradrenergic Systems and Somatic Symptoms in Psychiatric Disorders. *Front Psychiatry*. 2019 May 21;10:286. doi:10.3389/fpsyt.2019.00286.

18. Sklerov M, Dayan E, Browner N. Functional neuroimaging of the central autonomic network: recent developments and clinical implications. *Clin Auton Res*. 2019 Dec;29(6):555–66. doi:10.1007/s10286-018-0577-0.
19. Lamotte G, Shouman K, Benarroch EE. Stress and central autonomic network. *Auton Neurosci*. 2021 Nov;235:102870. doi:10.1016/j.autneu.2021.102870.
20. Starr LR, Hammen C, Brennan PA, Najman JM. Serotonin transporter gene as a predictor of stress generation in depression. *J Abnorm Psychol*. 2012 Nov;121(4):810–8. doi:10.1037/a0027952.
21. Shadrina M, Bondarenko EA, Slominsky PA. Genetics Factors in Major Depression Disease. *Front Psychiatry*. 2018 Jul 23;9:334. doi:10.3389/fpsyt.2018.00334.
22. Sánchez-Manso JC, Gujarathi R, Varacallo MA. Autonomic Dysfunction. In: StatPearls. Treasure Island (FL): StatPearls Publishing; [updated 2023 Aug 4].
23. Maltese PE, Manara E, Beccari T, Dundar M, Capodicasa N, Bertelli M. Genetic testing for autonomic dysfunction or dysautonomias. *Acta Biomed*. 2020 Nov 9;91(13-S):e2020002. doi:10.23750/abm.v91i13-S.10518.
24. Open Resources for Nursing (Open RN); Ernstmeyer K, Christman E, editors. Chapter 4 Autonomic Nervous System. In: *Nursing Pharmacology* [Internet]. 2nd edition. Eau Claire (WI): Chippewa Valley Technical College; 2023.
25. Thaisetthawatkul P. Pure Autonomic Failure. *Curr Neurol Neurosci Rep*. 2016 Aug;16(8):74. doi:10.1007/s11910-016-0673-2.
26. Luo Y, Yang N, Yang W, Chen B, Zhu S, Wu Y, Wang Q. Autonomic dysfunction in multiple system atrophy: from pathophysiology to clinical manifestations. *Ann Med*. 2025 Dec;57(1):2488111. doi:10.1080/07853890.2025.2488111.
27. Patwari PP, Carroll MS, Rand CM, Kumar R, Harper R, Weese-Mayer DE. Congenital central hypoventilation syndrome and the PHOX2B gene: a model of respiratory and autonomic dysregulation. *Respir Physiol Neurobiol*. 2010 Oct 31;173(3):322–35. doi:10.1016/j.resp.2010.06.013.
28. Verrotti A, Prezioso G, Scattoni R, Chiarelli F. Autonomic neuropathy in diabetes mellitus. *Front Endocrinol (Lausanne)*. 2014 Dec 1;5:205. doi:10.3389/fendo.2014.00205.
29. De León AM, Garcia-Santibanez R, Harrison TB. Article Topic: Neuropathies Due to Infections and Antimicrobial Treatments. *Curr Treat Options Neurol*. 2023 Jun 10:1–17. doi:10.1007/s11940-023-00756-5.
30. Giannas R, Klironomou L, Skafida E. A Case of Guillain-Barré Syndrome Possibly Associated With COVID-19 Infection. *Cureus*. 2025 Apr 24;17(4):e82954. doi:10.7759/cureus.82954.
31. Allan LM. Diagnosis and Management of Autonomic Dysfunction in Dementia Syndromes. *Curr Treat Options Neurol*. 2019 Jul 10;21(8):38. doi:10.1007/s11940-019-0581-2.
32. Palermo G, Del Prete E, Bonuccelli U, Ceravolo R. Early autonomic and cognitive dysfunction in PD, DLB and MSA: blurring the boundaries between α-synucleinopathies. *J Neurol*. 2020 Dec;267(12):3444–56. doi:10.1007/s00415-020-09985-z.
33. Staff NP, Windebank AJ. Peripheral neuropathy due to vitamin deficiency, toxins, and medications. *Continuum (Minneap Minn)*. 2014 Oct;20(5 Peripheral Nervous System Disorders):1293–306. doi:10.1212/01.CON.0000455880.06675.5a.
34. Won E, Kim YK. Stress, the Autonomic Nervous System, and the Immune-kynurenine Pathway in the Etiology of Depression. *Curr Neuropharmacol*. 2016;14(7):665–73. doi:10.2174/1570159x14666151208113006.
35. Sgoifo A, Carnevali L, Alfonso Mde L, Amore M. Autonomic dysfunction and heart rate variability in depression. *Stress*. 2015;18(3):343–52. doi:10.3109/10253890.2015.1045868.
36. Thayer JF, Brosschot JF. Psychosomatics and psychopathology: looking up and down from the brain. *Psychoneuroendocrinology*. 2005 Nov;30(10):1050–8. doi:10.1016/j.psyneuen.2005.04.014.
37. Siciliano RE, Anderson AS, Compas BE. Autonomic nervous system correlates of posttraumatic stress symptoms in youth: Meta-analysis and qualitative review. *Clin Psychol Rev*. 2022 Mar;92:102125. doi:10.1016/j.cpr.2022.102125.
38. Jiang Y, Zou D, Li Y, Gu S, Dong J, Ma X, et al. Monoamine Neurotransmitters Control Basic Emotions and Affect Major Depressive Disorders. *Pharmaceuticals (Basel)*. 2022 Sep 28;15(10):1203. doi:10.3390/ph15101203.
39. Perrotta G, Liberati AS, Eleuteri S. Neuroanatomical and Functional Correlates in Depressive Spectrum: A Narrative Review. *J Pers Med*. 2025;15(10):478. doi:10.3390/jpm15100478.
40. Castanheira L, Silva C, Cheniaux E, Telles-Correia D. Neuroimaging Correlates of Depression-Implications to Clinical Practice. *Front Psychiatry*. 2019 Oct 1;10:703. doi:10.3389/fpsyt.2019.00703.
41. Gross JJ. Emotion regulation: Current status and future prospects. *Psychol Inq*. 2015;26(1):1–26. doi:10.1080/1047840X.2014.940781.
42. Hamann S, Canli T. Individual differences in emotion processing. *Curr Opin Neurobiol*. 2004 Apr;14(2):233–8. doi:10.1016/j.conb.2004.03.010.
43. Porges SW. The polyvagal perspective. *Biol Psychol*. 2007 Feb;74(2):116–43. doi:10.1016/j.biopsycho.2006.06.009.
44. Critchley HD. Neural mechanisms of autonomic, affective, and cognitive integration. *J Comp Neurol*. 2005 Dec 5;493(1):154–66. doi:10.1002/cne.20749.
45. Candia-Rivera D, Catrambone V, Thayer JF, Gentili C, Valenza G. Cardiac sympathetic-vagal activity initiates a functional brain-body response to emotional arousal. *Proc Natl Acad Sci U S A*. 2022 May 24;119(21):e2119599119. doi:10.1073/pnas.2119599119.
46. Beissner F, Meissner K, Bär KJ, Napadow V. The autonomic brain: an activation likelihood estimation meta-analysis for central processing of autonomic function. *J Neurosci*. 2013 Jun 19;33(25):10503–11. doi:10.1523/JNEUROSCI.1103-13.2013.
47. Hsueh B, Chen R, Jo Y, Tang D, Raffiee M, Kim YS, et al. Cardiogenic control of affective behavioural state. *Nature*. 2023 Mar;615(7951):292–9. doi:10.1088/s41586-023-05748-8.
48. Khemani P, Mehdirad AA. Cardiovascular Disorders Mediated by Autonomic Nervous System Dysfunction. *Cardiol Rev*. 2020 Mar/Apr;28(2):65–72. doi:10.1097/CRD.0000000000000280.
49. Pfeiffer RF. Autonomic Dysfunction in Parkinson's Disease. *Neurotherapeutics*. 2020 Oct;17(4):1464–79. doi:10.1007/s13311-020-00897-4.
50. Gottlieb M. The Role of Autonomic Dysfunction in the Disease Pathogenesis of Gastroparesis. *J Hepatol Gastroint Dis*. 2023;9:257. doi:10.35248/2475-1318.23.9.257.
51. Dimino J, Kuo B. Current Concepts in Gastroparesis and Gastric Neuromuscular Disorders-Pathophysiology, Diagnosis, and Management. *Diagnostics (Basel)*. 2025 Apr 5;15(7):935. doi:10.3390/diagnostics15070935.
52. Kim JC, Joo KJ, Kim JT, Choi JB, Cho DS, Won YY. Alteration of autonomic function in female urinary incontinence. *Int Neurourol J*. 2010 Dec;14(4):232–7. doi:10.5213/inj.2010.14.4.232.

53. Coon EA, Cheshire WP Jr. Sweating Disorders. *Continuum (Minneap Minn)*. 2020 Feb;26(1):116–37. doi:10.1212/CON.0000000000000813.
54. Palma JA, Kaufmann H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. *Mov Disord*. 2018 Mar;33(3):372–90. doi:10.1002/mds.27344.
55. Palma JA, Thijs RD. Non-Pharmacological Treatment of Autonomic Dysfunction in Parkinson's Disease and Other Synucleinopathies. *J Parkinsons Dis*. 2024;14(s1):S81–92. doi:10.3233/JPD-230173.
56. Chen B, Yang W, Luo Y, Tan EK, Wang Q. Non-pharmacological and drug treatment of autonomic dysfunction in multiple system atrophy: current status and future directions. *J Neurol*. 2023 Nov;270(11):5251–73. doi:10.1007/s00415-023-11876-y.
57. Erkkinen MG, Kim MO, Geschwind MD. Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. *Cold Spring Harb Perspect Biol*. 2018 Apr 2;10(4):a033118. doi:10.1101/cshperspect.a033118.
58. Alkhowaiter S, Al Rasheed MM, Alammar N, Alotaibi A, Altuwaijri M, Alshankiti S, et al. Safety of prolonged use of metoclopramide and domperidone as treatment for chronic gastrointestinal dysmotility disorders in patients with systemic sclerosis. *Saudi Pharm J*. 2024 May;32(5):102039. doi:10.1016/j.jsps.2024.102039.
59. Kang K, Shi K, Liu J, Li N, Wu J, Zhao X. Autonomic dysfunction and treatment strategies in intracerebral hemorrhage. *CNS Neurosci Ther*. 2024 Feb;30(2):e14544. doi:10.1111/cns.14544.
60. Goldberger JJ, Arora R, Buckley U, Shivkumar K. Autonomic Nervous System Dysfunction: JACC Focus Seminar. *J Am Coll Cardiol*. 2019 Mar 19;73(10):1189–206. doi:10.1016/j.jacc.2018.12.064.
61. Blitshteyn S. Dysautonomia: a common comorbidity of systemic disease. *Immunol Res*. 2025 Jul 8;73(1):105. doi:10.1007/s12026-025-09661-2.
62. Ryu T, Adler BL, Jeong SJ, Lee DC, Hoke A, Na CH, et al. Quantitative serum proteomic analysis for biomarker discovery in post-COVID-19 postural orthostatic tachycardia syndrome (PC-POTS) patients. *Auton Neurosci*. 2025 Apr;258:103247. doi:10.1016/j.autneu.2025.103247.